Timo Minssen

Jan 17, 2025 | nature.com | Cristina Legido-Quigley |Timo Minssen |Filip Ottosson |Peter Rossing

Contemporary healthcare is undergoing a transition, shifting from a population-based approach to personalized medicine on an individual level1. In October 2023, the European Partnership for Personalized Medicine was officially launched2 to communicate the benefits of this approach to citizens and healthcare systems in member countries. The main debate revolves around the inconsistency in regulatory changes within personal data access and its potential commercialization.

Jan 15, 2025 | nature.com | Johnathon Liddicoat |Gabriela Lenarczyk |Mateo Aboy |Timo Minssen |Sebastian Mann

Can artificial intelligence improve clinical trial design? Despite their importance in medicine, over 40% of trials involve flawed protocols. We introduce and propose the development of application-specific language models (ASLMs) for clinical trial design across three phases: ASLM development by regulatory agencies, customization by Health Technology Assessment bodies, and deployment to stakeholders. This strategy could enhance trial efficiency, inclusivity, and safety, leading to more representative, cost-effective clinical trials.

Nov 12, 2024 | nature.com | Sebastian Mann |Anuraag A Vazirani |Brian D. Earp |Timo Minssen |I. Glenn Cohen

In this Comment, we propose a cumulative set of three essential criteria for the ethical use of LLMs in academic writing, and present a statement that researchers can quote when submitting LLM-assisted manuscripts in order to testify to their adherence to them.

Sep 5, 2024 | nature.com | Mateo Aboy |Timo Minssen |Effy Vayena

The newly adopted EU AI Act represents a pivotal milestone that heralds a new era of AI regulation across industries. With its broad territorial scope and applicability, this comprehensive legislation establishes stringent requirements for AI systems. In this article, we analyze the AI Act’s impact on digital medical products, such as medical devices: How does the AI Act apply to AI/ML-enabled medical devices? How are they classified? What are the compliance requirements?